DAVID LONARD to Neoplasms
This is a "connection" page, showing publications DAVID LONARD has written about Neoplasms.
Connection Strength
0.933
-
Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment. Breast Cancer Res. 2022 10 31; 24(1):73.
Score: 0.274
-
Reply to: Target expression is a relevant factor in synthetic lethal screens. Commun Biol. 2022 08 19; 5(1):836.
Score: 0.270
-
Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer. Clin Cancer Res. 2016 Nov 15; 22(22):5403-5407.
Score: 0.179
-
Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. J Med Chem. 2024 04 11; 67(7):5333-5350.
Score: 0.075
-
Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell. 2015 Aug 10; 28(2):240-52.
Score: 0.041
-
Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One. 2014; 9(4):e95243.
Score: 0.038
-
Nuclear receptor coactivators: master regulators of human health and disease. Annu Rev Med. 2014; 65:279-92.
Score: 0.036
-
Steroid receptor coactivators in Treg and Th17 cell biology and function. Front Immunol. 2024; 15:1389041.
Score: 0.019